[HTML][HTML] Fibroblast activation protein-based theranostics in cancer research: a state-of-the-art review

L Zhao, J Chen, Y Pang, K Fu, Q Shang, H Wu… - Theranostics, 2022 - ncbi.nlm.nih.gov
In recent years, quinoline-based fibroblast activation protein (FAP) inhibitors (FAPI) have
shown promising results in the diagnosis of cancer and several other diseases, making them …

Nanomedicine embraces cancer radio-immunotherapy: mechanism, design, recent advances, and clinical translation

H Li, Q Luo, H Zhang, X Ma, Z Gu, Q Gong… - Chemical Society …, 2023 - pubs.rsc.org
Cancer radio-immunotherapy, integrating external/internal radiation therapy with immuno-
oncology treatments, emerges in the current management of cancer. A growing number of …

Clinical summary of fibroblast activation protein inhibitor-based radiopharmaceuticals: cancer and beyond

M Li, MH Younis, Y Zhang, W Cai, X Lan - European journal of nuclear …, 2022 - Springer
Fibroblast activation protein (FAP) is a type II membrane-bound glycoprotein which is
overexpressed in cancer-associated fibroblasts and activated fibroblasts at wound …

[HTML][HTML] FAPI-PET/CT in cancer imaging: a potential novel molecule of the century

R Huang, Y Pu, S Huang, C Yang, F Yang, Y Pu… - Frontiers in …, 2022 - frontiersin.org
Fibroblast activation protein (FAP), a type II transmembrane serine protease, is highly
expressed in more than 90% of epithelial tumors and is closely associated with various …

Rational design and pharmacomodulation of protein-binding theranostic radioligands for targeting the fibroblast activation protein

L Meng, J Fang, L Zhao, T Wang, P Yuan… - Journal of Medicinal …, 2022 - ACS Publications
The fibroblast activation protein (FAP), overexpressed on cancer-associated fibroblasts
(CAFs), has become a valuable target for tumor diagnosis and therapy. However, most FAP …

Clinical evaluation of 68Ga-FAPI-RGD for imaging of fibroblast activation protein and integrin αvβ3 in various cancer types

L Zhao, X Wen, W Xu, Y Pang, L Sun… - Journal of Nuclear …, 2023 - Soc Nuclear Med
Radiolabeled fibroblast activation protein (FAP) inhibitors (FAPIs) and Arg-Gly-Asp (RGD)
peptides have been extensively investigated for imaging of FAP-and integrin αvβ3–positive …

Imaging-guided targeted radionuclide tumor therapy: From concept to clinical translation

J Sun, Z Huangfu, J Yang, G Wang, K Hu, M Gao… - Advanced Drug Delivery …, 2022 - Elsevier
Since the first introduction of sodium iodide I-131 for use with thyroid patients almost 80
years ago, more than 50 radiopharmaceuticals have reached the markets for a wide range …

Development of fibroblast activation protein inhibitor-based dimeric radiotracers with improved tumor retention and antitumor efficacy

L Zhao, J Chen, Y Pang, J Fang, K Fu… - Molecular …, 2022 - ACS Publications
Fibroblast activation protein (FAP), a fundamental component of the tumor stroma, is
overexpressed in cancer-associated fibroblasts (CAFs). As a promising theranostic probe …

Hetero-bivalent agents targeting FAP and PSMA

S Boinapally, A Lisok, G Lofland, I Minn, Y Yan… - European Journal of …, 2022 - Springer
Purpose We developed a theranostic radiopharmaceutical that engages two key cell surface
proteases, fibroblast activation protein alpha (FAP) and prostate-specific membrane antigen …

[HTML][HTML] Novel generation of FAP inhibitor-based homodimers for Improved Application in Radiotheranostics

M Martin, S Ballal, MP Yadav, C Bal, Y Van Rymenant… - Cancers, 2023 - mdpi.com
Simple Summary Radiopharmaceuticals targeting the fibroblast activation protein alpha
(FAP) can be used in many different cancer types since FAP is highly expressed in the tumor …